Cyclopentamine

Identification

Name
Cyclopentamine
Accession Number
DB08999
Type
Small Molecule
Groups
Withdrawn
Description

Cyclopentamine is a sympathomimetic alkylamine, classified as a vasoconstrictor. Cyclopentamine was indicated in the past as an over-the-counter medication for use as a nasal decongestant, notably in Europe and Australia, but has now been largely discontinued possibly due to the availability, effectiveness, and safety of a structurally similar drug, propylhexedrine.

Structure
Thumb
Synonyms
Not Available
Product Ingredients
IngredientUNIICASInChI Key
Cyclopentamine hydrochlorideF551446KF3538-02-3XGZPRABQSGUFBL-UHFFFAOYSA-N
Categories
UNII
WB9Q6M8O60
CAS number
102-45-4
Weight
Average: 141.258
Monoisotopic: 141.151749616
Chemical Formula
C9H19N
InChI Key
HFXKQSZZZPGLKQ-UHFFFAOYSA-N
InChI
InChI=1S/C9H19N/c1-8(10-2)7-9-5-3-4-6-9/h8-10H,3-7H2,1-2H3
IUPAC Name
(1-cyclopentylpropan-2-yl)(methyl)amine
SMILES
CNC(C)CC1CCCC1

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
5-(2-methylpiperazine-1-sulfonyl)isoquinolineThe risk or severity of adverse effects can be increased when 5-(2-methylpiperazine-1-sulfonyl)isoquinoline is combined with Cyclopentamine.
AcetazolamideThe risk or severity of adverse effects can be increased when Acetazolamide is combined with Cyclopentamine.
Acetyl sulfisoxazoleThe risk or severity of adverse effects can be increased when Acetyl sulfisoxazole is combined with Cyclopentamine.
AmikacinThe risk or severity of adverse effects can be increased when Amikacin is combined with Cyclopentamine.
AzosemideThe risk or severity of adverse effects can be increased when Azosemide is combined with Cyclopentamine.
BendroflumethiazideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Cyclopentamine.
BenzthiazideThe risk or severity of adverse effects can be increased when Benzthiazide is combined with Cyclopentamine.
Botulinum Toxin Type AThe risk or severity of adverse effects can be increased when Botulinum Toxin Type A is combined with Cyclopentamine.
Botulinum Toxin Type BThe risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Cyclopentamine.
BumetanideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Cyclopentamine.
Food Interactions
Not Available

References

Synthesis Reference

U.S. Patent 2,520,015.

General References
Not Available
External Links
KEGG Drug
D07370
PubChem Compound
7608
PubChem Substance
310264960
ChemSpider
7326
BindingDB
81456
ChEBI
134766
ChEMBL
CHEMBL329203
Wikipedia
Cyclopentamine
ATC Codes
R01AA02 — Cyclopentamine

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)113-115U.S. Patent 2,520,015.
Predicted Properties
PropertyValueSource
Water Solubility0.476 mg/mLALOGPS
logP2.86ALOGPS
logP2.26ChemAxon
logS-2.5ALOGPS
pKa (Strongest Basic)10.61ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count1ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area12.03 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity44.93 m3·mol-1ChemAxon
Polarizability18.4 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as dialkylamines. These are organic compounds containing a dialkylamine group, characterized by two alkyl groups bonded to the amino nitrogen.
Kingdom
Organic compounds
Super Class
Organic nitrogen compounds
Class
Organonitrogen compounds
Sub Class
Amines
Direct Parent
Dialkylamines
Alternative Parents
Organopnictogen compounds / Hydrocarbon derivatives
Substituents
Secondary aliphatic amine / Organopnictogen compound / Hydrocarbon derivative / Aliphatic homomonocyclic compound
Molecular Framework
Aliphatic homomonocyclic compounds
External Descriptors
Not Available

Drug created on June 17, 2014 09:42 / Updated on October 01, 2018 16:52